CAROL BIVINS: Open Payments
NPI 1154935880 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,181 in 103 payments from 15 companies in 2025. Trend: 2023 $2,391 · 2024 $2,327 · 2025 $2,181
Food & beverage: $2,181
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $620 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $410 |
| GENZYME CORPORATION | 5 | $245 |
| Regeneron Healthcare Solutions, Inc. | 5 | $158 |
| Aimmune Therapeutics, Inc. | 9 | $157 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $139 |
| QOL Medical, LLC | 5 | $112 |
| Madrigal Pharmaceuticals | 4 | $73 |
| Ipsen Biopharmaceuticals, Inc | 3 | $63 |
| Ardelyx, Inc. | 3 | $44 |
Products named: DUPIXENT, RINVOQ, ENTYVIO, XIFAXAN, ZENPEP, Sucraid, EOHILIA, REZDIFFRA.
Industry payments across MO — which companies pay providers there.
